Kopran Limited is an integrated pharmaceutical company that engages in the manufacture and marketing of active pharmaceutical ingredients (APIs) and finished dosage forms in India and internationally. The company was incorporated in 1958 and is based in Mumbai, India. Established on April 26, 1958, it was promoted by the Somani group and is currently controlled by Parijat Enterprises.
Kopran Limited and its subsidiary, Kopran Research Laboratories Limited, have established a strong presence in manufacturing an extensive spectrum of Finished Dosage Forms and Active Pharmaceutical Ingredients (APIs), respectively. With over sixty years of expertise, the company has adeptly seized opportunities and propelled a trajectory of sustained growth.
Kopran Ltd. operates through two primary business units: Formulations and Active Pharmaceutical Ingredients (APIs).
The API vertical, which constitutes approximately 54% of the business, is operated by the wholly-owned subsidiary Kopran Research Laboratories. This division undertakes the development, manufacturing, and sale of diverse Active Pharmaceutical Ingredients and Advanced Intermediates. Kopran is one of the leaders in Atenolol. The company's product portfolio includes over 30 APIs across multiple therapeutic segments, including Antibiotics, Carbapenems, Macrolides, Tetracycline, Antidiabetics, Anticoagulants, and Cardiovascular drugs.
The formulations division offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, covering both branded and generic formulations. It provides drugs in categories such as macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-acne, anti-infective, anti-thrombotic, antidiabetic, pain management, neuromodular, gastroenterology, and cardiovascular.
The company possesses state-of-the-art manufacturing facilities located in Mahad (housing APIs plant) and Khopoli (housing finished dosage forms plants). As part of its ongoing growth and expansion strategy, an API facility at GIDC – Panoli, Gujarat, was acquired by Kopran Research Laboratories Limited. Post-acquisition, this facility has been upgraded to a State-of-the-Art Integrated API facility, enabling the addition of newer molecules and offering cost competitiveness.
Kopran operates two API Facilities spanning 27,000 sqm, 9,000 sqm, and 8,500 sqm at Mahad – Maharashtra and Panoli – Gujarat. These API facilities have undergone successful inspections and approvals by leading regulatory bodies including USFDA, EDQM, EU GMP (France), WHO (Geneva), TGA (Australia), DMA (Denmark), AIFA (Italy), AFSSAPS (France), and MFDS (South Korea).
Kopran Limited has established its presence in more than 60 countries, including African nations, South Africa, the United States, Latin America, Southeast Asia, the European Union, China, Australia, the CIS region, and the United Kingdom. With over 500 registrations and operations in more than 30 countries across Europe, Asia, Africa, Latin & South America, and the Middle East, the company reaches a large number of customers as a reputed and responsible manufacturer.
With a team of over 40 scientists, Kopran's R&D division offers solutions across the entire product development value chain. This includes strategic sourcing, IP management, formulation development, analytical method development and validation, technology transfer, bio-equivalence, packaging development, and global regulatory submissions. The R&D facility is equipped with state-of-the-art infrastructure capable of handling approximately 30 new product development projects simultaneously.
Kopran Limited's financial performance reflects its position in the pharmaceutical industry.
For the full year ended March 2025, Kopran Limited reported a net profit decline of 24.35% to ₹38.55 crore, compared to ₹50.96 crore in the previous year (March 2024). Sales, however, increased by 2.44% to ₹629.60 crore in the year ended March 2025, up from ₹614.59 crore during the previous year ended March 2024.
• Revenue: ₹630 Crore (FY 2025)
• Net Profit: ₹38.6 Crore (FY 2025)
• Market Capitalization: ₹900.09 Crore (as of July 2, 2025)
• P/E Ratio: 23.34
• P/B Ratio: 1.83
• ROE: 8.32% (over last 3 years)
• Dividend Yield: 1.61%
• Promoter Holding: 44.42% (as of March 2025)
The United States Food and Drug Administration (USFDA) recently conducted a surveillance inspection at Kopran Research Laboratories, the company's wholly-owned subsidiary. The inspection, carried out at the API manufacturing unit located in Mahad, Maharashtra, between April 21 and April 25, 2025, concluded without any observations, as confirmed by Kopran in a regulatory filing.
Kopran's Annual Secretarial Compliance Report for FY 2025 indicates full regulatory compliance with no major violations. The company has also declared a dividend of ₹3, subject to shareholder approval.
Kopran Ltd (KOPRAN) operates within the Health Care sector and Pharmaceuticals sub-sector. The 52-week high for Kopran Ltd is ₹369.70, and the 52-week low is ₹155. Over the past six months, the Kopran share price has decreased by 14.53%, and in the last one year, it has decreased by 22.11%.
The company continues to focus on expanding its global footprint while maintaining its position as a leading manufacturer of pharmaceutical formulations and APIs, backed by strong regulatory compliance across multiple international markets.
